PIK3CD and acute lymphoblastic leukemia: Although this study found that efficacy observed in ALL patients warrant further clinical exploration into dual PI3K/mTOR inhibitors, in particular patients with Ph + BCP-ALL or T-ALL may benefit from these treatments (Ref.